pSivida’s lead investigational new product is a three-year sustained-release implant containing fluocinolone acetonide , a corticosteroid, in late stage clinical development for the treatment of posterior uveitis. The product utilizes the proven Durasert Technology platform. The first Phase 3 study achieved its primary endpoint with high statistical significance. The second Phase 3 study results are expected first half of 2017. Filing in the EU is anticipated first half of 2017 and second half of 2017 in the U.S.
- pSivida Corp. Achieves Significant Milestones Throughout FY 2017; Reports Fourth Quarter and Fiscal 2017 Results
- pSivida to Present at Rodman & Renshaw Annual Global Investment Conference
- pSivida Corp. to Report Fourth Quarter and Fiscal Year 2017 Financial Results on Monday, September 11th